Mc Adam, LLC Cassava Sciences Inc Transaction History

Mc Adam, LLC

$1.77 Billion
Q3 2024

A detailed history of Mc Adam, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Mc Adam, LLC holds 7,057 shares of SAVA stock, worth $186,869. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,057

Holding current value

$186,869

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	BUY	$9.57 - $35.08 $67,535 - $247,559	7,057 New	7,057 $207,000
Q4 2022 Jan 27, 2023	SELL	$27.82 - $44.16 $2,281 - $3,621	-82 Reduced 1.32%	6,108 $267,000
Q3 2022 Oct 24, 2022	BUY	$16.33 - $51.06 $101,082 - $316,061	6,190 New	6,190 $259,000
Q2 2022 Jul 15, 2022	SELL	$17.22 - $38.47 $106,918 - $238,860	-6,209 Closed	0 $0
Q1 2022 Apr 07, 2022	BUY	$32.6 - $53.05 $3,292 - $5,358	101 Added 1.65%	6,209 $231,000
Q4 2021 Jan 07, 2022	SELL	$36.77 - $90.91 $9,523 - $23,545	-259 Reduced 4.07%	6,108 $267,000
Q3 2021 Oct 05, 2021	BUY	$41.79 - $135.3 $37,736 - $122,175	903 Added 16.53%	6,367 $395,000
Q2 2021 Aug 02, 2021	BUY	$32.15 - $89.72 $3,407 - $9,510	106 Added 1.98%	5,464 $565,000
Q1 2021 Apr 26, 2021	BUY	$7.09 - $87.95 $37,988 - $471,236	5,358 New	5,358 $241,000

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

Black Rock Inc. New York, NY

3.22M
Shares

$85.3 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.52M
Shares

$66.8 Million
0.0% of portfolio
State Street Corp Boston, MA

1.16M
Shares

$30.8 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.01M
Shares

$26.7 Million
0.0% of portfolio
Gallacher Capital Management LLC Lone Tree, CO

580K
Shares

$15.4 Million
7.83% of portfolio

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.06B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Adam, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mc Adam, LLC with notifications on news.

Account